Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRNX 
Crinetics Pharmaceuticals Inc (CRNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CRNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $69.38
1 Year Target Price $69.38
| 11 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.91% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.89B USD | Price to earnings Ratio - | 1Y Target Price 69.38 |
Price to earnings Ratio - | 1Y Target Price 69.38 | ||
Volume (30-day avg) 17 | Beta 0.33 | 52 Weeks Range 24.10 - 62.53 | Updated Date 08/28/2025 |
52 Weeks Range 24.10 - 62.53 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.13 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -1.1 | Actual -1.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -12522.99% |
Management Effectiveness
Return on Assets (TTM) -23.77% | Return on Equity (TTM) -36.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1716526217 | Price to Sales(TTM) 2073.63 |
Enterprise Value 1716526217 | Price to Sales(TTM) 2073.63 | ||
Enterprise Value to Revenue 1233.14 | Enterprise Value to EBITDA -13.4 | Shares Outstanding 94176000 | Shares Floating 92780306 |
Shares Outstanding 94176000 | Shares Floating 92780306 | ||
Percent Insiders 2.01 | Percent Institutions 114.6 |
Upturn AI SWOT
Crinetics Pharmaceuticals Inc
Company Overview
History and Background
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Founded in 2008, Crinetics has progressed from early-stage research to clinical development, focusing on oral, small molecule therapeutics.
Core Business Areas
- Endocrine Diseases: Focuses on developing treatments for acromegaly, Cushing's disease, hyperinsulinism, and other endocrine disorders.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Drug Discovery: Research and development of novel therapeutics using their proprietary drug discovery platform.
Leadership and Structure
The leadership team includes Scott Struthers (Founder and CEO), Marc Wilson (Chief Financial Officer), and other experienced pharmaceutical executives. The company structure supports research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Paltusotine (CRN04777): An investigational, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist being developed for the treatment of acromegaly. It aims to provide an oral alternative to injectable somatostatin analogs. Competitors include injectable drugs from Novartis (Sandostatin, Pasireotide) and Chiasma (Mycapssa). Market share data for Paltusotine is not yet available as it is still in development. If successful, it will compete with Sandostatin, Pasireotide, and Mycapssa.
- CRN04894: An investigational, oral ACTH antagonist being developed for the treatment of Cushing's disease and congenital adrenal hyperplasia (CAH). It offers a new approach to manage cortisol levels. Competitors include Corcept Therapeutics (Korlym, relacorilant). Market share data is unavailable, as it's in development. If approved, it will compete directly with Korlym and potentially relacorilant.
Market Dynamics
Industry Overview
The pharmaceutical industry specializing in rare endocrine diseases is characterized by high unmet needs and potential for orphan drug designation, which offers market exclusivity. The industry focuses on developing targeted therapies with improved efficacy and safety profiles.
Positioning
Crinetics is positioned as an innovator in the field of oral, small molecule endocrine therapeutics. Its competitive advantage lies in its proprietary drug discovery platform and focus on addressing unmet needs with convenient oral therapies.
Total Addressable Market (TAM)
The TAM for rare endocrine diseases is estimated to be in the billions of dollars, with significant growth potential. Crinetics is positioned to capture a portion of this market with its oral therapies offering improved convenience and patient compliance compared to existing injectable treatments.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Focus on oral small molecule therapeutics
- Strong intellectual property portfolio
- Experienced management team
- Targeting underserved rare endocrine diseases
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- High research and development costs
- Competition from established pharmaceutical companies
Opportunities
- Potential for orphan drug designation and market exclusivity
- Expansion into new endocrine disease areas
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results driving stock appreciation
- Growing awareness of rare endocrine diseases
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from biosimilars or generics
- Changes in healthcare reimbursement policies
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- MNKD
- CORT
Competitive Landscape
Crinetics competes with established pharmaceutical companies with existing products for endocrine diseases. Its advantage lies in its oral therapies potentially offering improved convenience and patient compliance. However, these must overcome regulatory hurdles and be shown to be clinically significant to capture market share.
Growth Trajectory and Initiatives
Historical Growth: Growth primarily driven by the advancement of its clinical pipeline and successful fundraising activities.
Future Projections: Future growth hinges on clinical trial outcomes and potential regulatory approvals for Paltusotine and CRN04894. Analyst estimates would provide specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead drug candidates, securing partnerships, and strengthening its intellectual property position.
Summary
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline focused on oral therapies for rare endocrine diseases. While they have a novel drug discovery platform and target unmet needs, they face risks associated with clinical trials and competition from established players. Successful clinical trial outcomes for Paltusotine and CRN04894 are critical for their future growth, and the company needs to secure partnerships or additional funding to support its development efforts. They should also pay close attention to competitive threats to avoid losing market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate. Future projections are subject to change based on various factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crinetics Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-07-18 | Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 437 | Website https://www.crinetics.com |
Full time employees 437 | Website https://www.crinetics.com | ||
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.